Introduction:All countries face the potential threat of imported polioviruses,including both wild type and circulating vaccine-derived polioviruses.In response,we conducted a province-level assessment in China to eval...Introduction:All countries face the potential threat of imported polioviruses,including both wild type and circulating vaccine-derived polioviruses.In response,we conducted a province-level assessment in China to evaluate the risk of importation and transmission of type 1 wild poliovirus(WPV1)and type 2 vaccine-derived poliovirus(VDPV2).Methods:Distinct risk assessment tools for WPV1 and VDPV2 were employed,incorporating three primary indicators—population immunity,poliovirus surveillance,and importation risk.WPV1 was assessed using 13 secondary indicators,whereas VDPV2 utilized 21 secondary indicators.Assessments used comprehensive provincial data from the preceding five years.Scores(S-values)were derived from the secondary indicators’criteria and ratings,and used to classify the provincial-level administrative divisions(PLADs)into three risk categories:high,medium,and low.The top 10%of PLADs were designated as highrisk,with the remaining provinces equally distributed into medium-and low-risk categories.Results:In 2023,Xizang,Qinghai,and Xinjiang PLADs faced the highest risk of WPV1 importation and transmission;Xizang,Shaanxi,and Hainan PLADs were at the greatest risk for VDPV2 importation and transmission.Conclusions:Risk assessment for VDPV2 importation and transmission has identified a distinct set of high-risk provinces compared to those identified by WPV1 risk assessment.Preventive and proactive response measures tailored to the specific risks should be implemented to maintain China’s polio-free status.展开更多
Summary What is already known on this topic?In China,there is limited data available on the use and coverage of the non-program,combined diphtheria,tetanus toxoid,acellular pertussis adsorbed,inactivated poliovirus an...Summary What is already known on this topic?In China,there is limited data available on the use and coverage of the non-program,combined diphtheria,tetanus toxoid,acellular pertussis adsorbed,inactivated poliovirus and haemophilus influenzae type b(DTaPIPV/Hib)pentavalent vaccine,and its role as a substitute for the separately administered standalone program vaccines.展开更多
Summary What is already known on this topic?There is a lack of comprehensive data on the coverage of the human papillomavirus(HPV)vaccine in China.The limited published literature hampers our ability to accurately ass...Summary What is already known on this topic?There is a lack of comprehensive data on the coverage of the human papillomavirus(HPV)vaccine in China.The limited published literature hampers our ability to accurately assess the current situation.What is added by this report?展开更多
Summary What is already known on this topic?Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine(PCV13)in China.A lack of official statistics,coupled with an insufficient body of p...Summary What is already known on this topic?Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine(PCV13)in China.A lack of official statistics,coupled with an insufficient body of published literature,hinders the accurate depiction of the current situation.What is added by this report?This study investigated the utilization of PCV13 and estimated its coverage in nine provinces across eastern,central,and western China between 2019 and 2021.Despite an annual increase in PCV13 usage during this period,the overall coverage remained suboptimal.展开更多
基金Supported by the Evaluation of 2 Polio Vaccine Strategy Switches in China(JY22-3-10).
文摘Introduction:All countries face the potential threat of imported polioviruses,including both wild type and circulating vaccine-derived polioviruses.In response,we conducted a province-level assessment in China to evaluate the risk of importation and transmission of type 1 wild poliovirus(WPV1)and type 2 vaccine-derived poliovirus(VDPV2).Methods:Distinct risk assessment tools for WPV1 and VDPV2 were employed,incorporating three primary indicators—population immunity,poliovirus surveillance,and importation risk.WPV1 was assessed using 13 secondary indicators,whereas VDPV2 utilized 21 secondary indicators.Assessments used comprehensive provincial data from the preceding five years.Scores(S-values)were derived from the secondary indicators’criteria and ratings,and used to classify the provincial-level administrative divisions(PLADs)into three risk categories:high,medium,and low.The top 10%of PLADs were designated as highrisk,with the remaining provinces equally distributed into medium-and low-risk categories.Results:In 2023,Xizang,Qinghai,and Xinjiang PLADs faced the highest risk of WPV1 importation and transmission;Xizang,Shaanxi,and Hainan PLADs were at the greatest risk for VDPV2 importation and transmission.Conclusions:Risk assessment for VDPV2 importation and transmission has identified a distinct set of high-risk provinces compared to those identified by WPV1 risk assessment.Preventive and proactive response measures tailored to the specific risks should be implemented to maintain China’s polio-free status.
基金Supported by the Medical and Health Science and Technology Project of Zhejiang Province(2021KY625).
文摘Summary What is already known on this topic?In China,there is limited data available on the use and coverage of the non-program,combined diphtheria,tetanus toxoid,acellular pertussis adsorbed,inactivated poliovirus and haemophilus influenzae type b(DTaPIPV/Hib)pentavalent vaccine,and its role as a substitute for the separately administered standalone program vaccines.
基金Lance Everett Rodewald for his assistance in editing the article and providing valuable feedback.
文摘Summary What is already known on this topic?There is a lack of comprehensive data on the coverage of the human papillomavirus(HPV)vaccine in China.The limited published literature hampers our ability to accurately assess the current situation.What is added by this report?
文摘Summary What is already known on this topic?Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine(PCV13)in China.A lack of official statistics,coupled with an insufficient body of published literature,hinders the accurate depiction of the current situation.What is added by this report?This study investigated the utilization of PCV13 and estimated its coverage in nine provinces across eastern,central,and western China between 2019 and 2021.Despite an annual increase in PCV13 usage during this period,the overall coverage remained suboptimal.
